A Study of JNJ-67835989 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

109

Participants

Timeline

Start Date

April 27, 2021

Primary Completion Date

May 18, 2022

Study Completion Date

May 18, 2022

Conditions

Healthy

Interventions

DRUG

JNJ-67835989

JNJ-67835989 will be administered orally.

DRUG

Placebo

Matching placebo will be administered orally.

Trial Locations (1)

Clinical Pharmacology Unit, Merksem

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY